Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

Healthcare & PharmaceuticalsRussia reaches deal to produce Sputnik V vaccine at Serbia's Torlak Institute - RDIF fund

Reuters
1 minute read

A vial labelled "Sputnik V Coronavirus COVID-19 Vaccine" and a syringe are seen in this illustration photo taken March 12, 2021. REUTERS/Dado Ruvic/Illustration

Russia's RDIF sovereign wealth fund said on Thursday it had reached an agreement with Serbia's Torlak Institute to produce the Sputnik V vaccine against COVID-19 there.

Our Standards: The Thomson Reuters Trust Principles.